The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 37 approved and 5 pipeline generic products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to an authorized generic version of Adderall XR
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Dobbies Garden Centres
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Giraffe restaurants
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Tesco plc, a listed FTSE 100 retailer, on its sale of the Giraffe casual dining restaurant chain to the Boparan Private Office, the private investment vehicle of the British businessman Ranjit Boparan
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Boehringer Ingelheim
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
![Italy Italy flag](https://www.greenhill.com/sites/default/files/italy.gif)
Antin Solar Investments
![UK/Switzerland U.K., Switzerland flags](https://www.greenhill.com/sites/default/files/uk_switzerland.gif)
Advised Antin Infrastructure Partners on its sale of Antin Solar Investments, a leading Italian solar platform, to a consortium of investors comprised of Swiss Life Asset Management and Quercus Investment Partners
![Swiss, Netherlands flags](https://www.greenhill.com/sites/default/files/swiss_netherlands_0.gif)
Airopack Technology Group AG
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
![Netherlands Netherlands flag](https://www.greenhill.com/sites/default/files/niederland.gif)
Stork
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Arle Capital Partners on the sale of Stork, an international provider of maintenance, modification and asset integrity services for large existing industrial facilities in the oil and gas, chemicals, industrial and power markets, to Fluor Corporation, one of the world’s largest publicly-traded engineering, procurement and construction companies
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Allied Healthcare
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
![South Africa/UK U.K., South Africa flags](https://www.greenhill.com/sites/default/files/safrica-uk.gif)
Lonmin Plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Lonmin Plc on its c.$777mm recapitalization consisting of c.$370mm of bank facilities at the Plc and in South Africa from the Company’s ten lending banks and a fully underwritten Rights Issue of c.$407mm.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Stemcor Holdings Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Stemcor Holdings Limited, the global steel trader, on their restructuring of $1.0bn of senior and junior debt and the refinancing of a $1.1bn working capital facility
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Allergan Generics
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Portfolio of GlaxoSmithKline plc consumer and OTC brands
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Tate & Lyle plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Tate & Lyle plc, a leading provider of ingredients and solutions to the food, beverage and other industries, on the re-alignment of Eaststarch C.V., its 50:50 corn wet milling joint venture in Europe with Archer Daniels Midland Company
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
AA plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised AA plc, the UK’s leading roadside assistance provider, on the refinancing of its high yield bond and PIK instrument
![Luxemboug Luxembourg flag](https://www.greenhill.com/sites/default/files/luxembourg.gif)
Azelis Group (majority owned by 3i)
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
TITAL GmbH
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Alcoa Inc. on the acquisition of TITAL GmbH, a privately-held German manufacturer of aluminum and titanium castings predominately for the aerospace and defense end markets
![Italy Italy flag](https://www.greenhill.com/sites/default/files/italy.gif)
Faster S.p.A.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised Capvis, one of the leading buyout firms in Switzerland, on the acquisition of Faster S.p.A., one of the top 2 global manufacturers of quick-release hydraulic couplings
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
MannKind Corporation
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.